Sign In
Last checked at 
27 May 2022 16:31
27 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of and changes to Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 200,000 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors and members of the Company's senior management team as part of their remuneration package and pursuant to the Company's Employee Share Option Plan ("ESOP"), and provides an update on the arrangements for the share options held by Philip White.
Share Options were granted as follows:
Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Effective Grant date |
Nick Roberts, CFO | 50,000 | 91,838 | 0.10% | 27 May 2022 |
Julie Browne, COO and PDMR | 50,000 | 101,938 | 0.12% | 27 May 2022 |
Stefan McDonald, CGO and PDMR | 50,000 | 131,722 | 0.16% | 27 May 2022 |
Other employees (1 person) | 50,000 | 96,051 | 0.11% | 27 May 2022 |
The Share Options issued to the Director and CFO, Nick Roberts, vest over three years from the point of employment start (being 18th March 2022) and are subject to continued employment.
The Share Options issued to Julie Browne and the other employee vest in tranches over a three-year period from the point of employment start (being 14th March 2022 and 1st January 2022 respectively), and to Stefan McDonald from the date of his promotion to the Company's senior management team (being 1st September 2021) and are subject to continued employment.
The exercise price of the Share Options granted is £0.002 per share which equates to the nominal value of the shares.
Following this grant, the total number of share options outstanding in the Company is 3,308,118, representing approximately 3.92% of its current issued share capital of 84,472,431.
Further to the announcement on 11 January 2022 and, as part of the orderly handover of duties Phillip White (former CFO and Director) is facilitating, the Board has agreed that all his outstanding share options would vest immediately (including those which are currently out of the money). As provided in the scheme rules, these options are require to be exercised within 90 days of vesting.
Phillip White's outstanding share options are as follows:
Number of Share Options outstanding | Grant date | Exercise price (pence) | Original vesting period | Original vesting conditions |
180,000 | 17 April 2020 | 126.5 | 3 years | Continued employment |
64,154 | 20 April 2021 | 0.2 | 3 years | Total Shareholder Return and continued employment |
The above arrangements with Philip White constitute a related party transaction under the AIM Rules for Companies. The directors, excluding Philip White who is no longer a director, consider, having consulted with the Company's nominated adviser, Stifel Nicolaus Europe Limited, that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.
Enquiries:
Diaceutics PLC | |
Peter Keeling, Chief Executive Officer | Via Alma PR |
Nick Roberts, Chief Financial Officer | |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison, Stewart Wallace, Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde, Kieran Breheny, Matthew Young | diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Nick Roberts | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | CFO, Director | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
Exercise price of 0.2p per share | 50,000 | ||||||
e. | Date of the transaction | 26 May 2022 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Julie Browne | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | COO and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
Exercise price of 0.2p per share | 50,000 | ||||||
e. | Date of the transaction | 26 May 2022 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stefan McDonald | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | CGO and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
Exercise price of 0.2p per share | 50,000 | ||||||
e. | Date of the transaction | 26 May 2022 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Philip White | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Change of original vesting conditions of share options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
Exercise price of 126.5p per share | 180,000 | ||||||
Exercise price of 0.2p per share | 64,154 | ||||||
e. | Date of the transaction | 26 May 2022 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Follow the stocks
